What is HC Wainwright’s Forecast for AARD Q2 Earnings?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) – HC Wainwright issued their Q2 2025 EPS estimates for Aardvark Therapeutics in a research note issued on Monday, June 30th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.45) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. HC Wainwright also issued estimates for Aardvark Therapeutics’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.18) EPS, Q1 2026 earnings at ($0.77) EPS, Q2 2026 earnings at ($0.87) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.34) EPS.

Aardvark Therapeutics (NASDAQ:AARD) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01).

Several other research analysts also recently commented on AARD. Morgan Stanley initiated coverage on Aardvark Therapeutics in a report on Monday, March 10th. They issued an “overweight” rating and a $29.00 price target for the company. Bank of America boosted their target price on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $50.00 target price on shares of Aardvark Therapeutics in a research report on Tuesday, April 1st. Wall Street Zen cut shares of Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. Finally, Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.00.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ:AARD opened at $13.52 on Wednesday. Aardvark Therapeutics has a 52 week low of $4.88 and a 52 week high of $19.58. The firm has a fifty day moving average price of $11.27.

Institutional Investors Weigh In On Aardvark Therapeutics

Large investors have recently bought and sold shares of the company. Walleye Capital LLC bought a new stake in Aardvark Therapeutics in the 1st quarter valued at $88,000. Goldman Sachs Group Inc. acquired a new position in shares of Aardvark Therapeutics during the first quarter worth about $153,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Aardvark Therapeutics during the first quarter worth about $1,878,000. Braidwell LP acquired a new stake in Aardvark Therapeutics in the 1st quarter valued at approximately $3,755,000. Finally, Cormorant Asset Management LP bought a new stake in Aardvark Therapeutics in the 1st quarter valued at approximately $6,009,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.